The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology
Open accessAbstract
Background: Exogenous replacement of erythropoietin (EPO) by recombinant human EPO has been considered a standard of care for the treatment of anemia in patients with chronic kidney disease for more than 20 years. Genetically engineered biologic proteins derived from human, animal, or microorganism sources are a major area of growth in modern medical care, accounting for one-third of new drug approvals in the past decade. Despite benefit to patients, the use of biologics comes at a significant cost, representing one of the fastest growing segments of strained healthcare budgets around the world. Summary: Biosimilars, or biologic drugs that are designed to be highly similar to approved reference biologic drugs, have been available in Europe for more than 10 years with no unusual or unexpected effects compared to their reference biologics whose patents have expired. Given the success of the biosimilar approval pathway pioneered in Europe, it has served as a global reference for other regulatory authorities to establish and implement biosimilar licensure frameworks, including the United States (US), the largest pharmaceutical market in the world. Given 10 of the top 25 drugs sold in 2014 were biologics, and considering the rising costs of healthcare, biosimilars have the potential to become a significant part of the US market. Key Messages: For the nephrology community, the recent patent expiries for epoetin alfa (Epogen®, Amgen and Procrit®, Johnson & Johnson) have created the opportunity to develop biosimilar EPOs. And while no biosimilar in this therapeutic class is approved in the US, there are proposed biosimilars in development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762 · cited 2×
“[17] The decision was based on key data obtained from the Normal Hematocrit Cardiac Trial (NHCT),[25] the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) study, [15] and the Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) study.[16] Briefly, the results of NHCT p…”
Andrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Cloning and expression of the human erythropoietin gene.
Lin, F. K., Suggs, S., Lin, C. H., Browne, J. K., Smalling, R., Egrie, J. C., Chen, K. K., Fox, G. M., Martin, F., & Stabinsky, Z. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.22.7580 · Cited by 1,134
Purification of human erythropoietin.
Miyake, T., Kung, C. K., & Goldwasser, E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)63387-9 · Cited by 886
Jones, M., Ibels, L., Schenkel, B., & Zagari, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 665
Pure Red-Cell Aplasia and Epoetin Therapy
Bennett, C. L., Luminari, S., Nissenson, A. R., Tallman, M. S., Klinge, S. A., McWilliams, N., McKoy, J. M., Kim, B., Lyons, E. A., Trifilio, S. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040528 · Cited by 437
How the Target Hemoglobin of Renal Anemia Should Be?
Mimura, I., Tanaka, T., & Nangaku, M. (2015) · Nephron · doi:10.1159/000440849 · Cited by 416
Boven, K., Stryker, S., Knight, J., Thomas, A., van Regenmortel, M., Kemeny, D. M., Power, D., Rossert, J., & Casadevall, N. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00340.x · Cited by 251
Seidl, A., Hainzl, O., Richter, M., Fischer, R., Böhm, S., Deutel, B., Hartinger, M., Windisch, J., Casadevall, N., London, G. M., et al. (2012) · Pharmaceutical Research · doi:10.1007/s11095-011-0621-4 · Cited by 202
Epoetin‐associated pure red cell aplasia: past, present, and future considerations
McKoy, J. M., Stonecash, R. E., Cournoyer, D., Rossert, J., Nissenson, A. R., Raisch, D. W., Casadevall, N., & Bennett, C. L. (2008) · Transfusion · doi:10.1111/j.1537-2995.2008.01749.x · Cited by 192
What's fueling the biotech engine?
Aggarwal, S. (2007) · Nature Biotechnology · doi:10.1038/nbt1007-1097 · Cited by 105
Macdougall, I. C., Roger, S. D., de Francisco, A., Goldsmith, D. J. A., Schellekens, H., Ebbers, H. C., JELKMANN, W. E. B., London, G. M., Casadevall, N., Hörl, W. H., et al. (2012) · Kidney International · doi:10.1038/ki.2011.500 · Cited by 100
Biosimilar epoetins and other “follow‐on” biologics: Update on the European experiences
JELKMANN, W. E. B. (2010) · American Journal of Hematology · doi:10.1002/ajh.21805 · Cited by 94
Haag–Weber, M., Eckardt, K., Hörl, W. H., Roger, S. D., Vetter, A., & Roth, K. (2011) · Clinical Nephrology · doi:10.5414/cn107304 · Cited by 93
Cournoyer, D., Toffelmire, E. B., Wells, G. A., Barber, D. L., Barrett, B. J., Delage, R., Forrest, D. L., Gagnon, R. F., Harvey, E. A., Laneuville, P., et al. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000140219.28618.9f · Cited by 83
Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks
Macdougall, I. C. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1087 · Cited by 81
Bello, N. A., Lewis, E. F., Desai, A. S., Anand, I. S., Krum, H., McMurray, J. J. V., Olson, K. A., Solomon, S. D., Swedberg, K. B., van Veldhuisen, D. J., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.412 · Cited by 45
Cited by
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Cloning and expression of the human erythropoietin gene.
Lin, F. K., Suggs, S., Lin, C. H., Browne, J. K., Smalling, R., Egrie, J. C., Chen, K. K., Fox, G. M., Martin, F., & Stabinsky, Z. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.22.7580 · Cited by 1,134
Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5680 · Cited by 990
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Matsushita, K., Ballew, S. H., Wang, A. Y.-M., Kalyesubula, R., Schaeffner, E., & Agarwal, R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00616-6 · Cited by 670
Metadata
- Authors
- Kalantar-Zadeh, K.
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 45
- Issue
- 3
- Pages
- 235-247
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- OpenAlex
- W2584947097
- Cited by
- 1,148
- References
- 21
- FWCI
- 34.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.